ISPOR - PCR104 How Do Chinese Draft Guidelines (2021) on Patient Focused Drug Development Compare with Those of EMA and FDA?

PCR104 How Do Chinese Draft Guidelines (2021) on Patient Focused Drug Development Compare with Those of EMA and FDA?

Abstract

Authors

M. Heinrich K. Rudell

Full Text Cite This Article

Back to Volume 26, Supplemental Issue 6S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now